vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Porch Group, Inc. (PRCH). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $121.1M, roughly 1.4× Porch Group, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 100.0%). Over the past eight quarters, Porch Group, Inc.'s revenue compounded faster (26.4% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Porch is a website that tries to connect homeowners with local home improvement contractors. The site features advice articles, cost guide, and online booking for over 160 home projects.
ESPR vs PRCH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $121.1M |
| Net Profit | — | $-4.7M |
| Gross Margin | — | 52.7% |
| Operating Margin | 50.6% | 34.7% |
| Net Margin | — | -3.9% |
| Revenue YoY | 143.7% | 100.0% |
| Net Profit YoY | — | 2.0% |
| EPS (diluted) | $0.32 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $121.1M | ||
| Q4 25 | $168.4M | $112.3M | ||
| Q3 25 | $87.3M | $115.1M | ||
| Q2 25 | $82.4M | $107.0M | ||
| Q1 25 | $65.0M | $84.5M | ||
| Q4 24 | $69.1M | $75.3M | ||
| Q3 24 | $51.6M | $77.7M | ||
| Q2 24 | $73.8M | $75.9M |
| Q1 26 | — | $-4.7M | ||
| Q4 25 | — | $-3.5M | ||
| Q3 25 | $-31.3M | $-10.9M | ||
| Q2 25 | $-12.7M | $2.6M | ||
| Q1 25 | $-40.5M | $8.4M | ||
| Q4 24 | — | $30.5M | ||
| Q3 24 | $-29.5M | $14.4M | ||
| Q2 24 | $-61.9M | $-64.3M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | — | 99.5% | ||
| Q3 25 | — | 75.6% | ||
| Q2 25 | — | 70.9% | ||
| Q1 25 | — | 77.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 79.4% | ||
| Q2 24 | — | 22.1% |
| Q1 26 | — | 34.7% | ||
| Q4 25 | 50.6% | 14.7% | ||
| Q3 25 | -11.4% | 14.2% | ||
| Q2 25 | 8.6% | 4.7% | ||
| Q1 25 | -34.0% | -1.5% | ||
| Q4 24 | -6.4% | 33.3% | ||
| Q3 24 | -31.0% | -3.2% | ||
| Q2 24 | 3.5% | -69.2% |
| Q1 26 | — | -3.9% | ||
| Q4 25 | — | -3.1% | ||
| Q3 25 | -35.9% | -9.4% | ||
| Q2 25 | -15.4% | 2.4% | ||
| Q1 25 | -62.2% | 9.9% | ||
| Q4 24 | — | 40.5% | ||
| Q3 24 | -57.2% | 18.5% | ||
| Q2 24 | -83.9% | -84.8% |
| Q1 26 | — | $-0.04 | ||
| Q4 25 | $0.32 | $0.00 | ||
| Q3 25 | $-0.16 | $-0.10 | ||
| Q2 25 | $-0.06 | $0.00 | ||
| Q1 25 | $-0.21 | $0.07 | ||
| Q4 24 | $-0.14 | $0.34 | ||
| Q3 24 | $-0.15 | $0.12 | ||
| Q2 24 | $-0.33 | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $68.4M |
| Total DebtLower is stronger | — | $391.3M |
| Stockholders' EquityBook value | $-302.0M | $26.3M |
| Total Assets | $465.9M | $806.6M |
| Debt / EquityLower = less leverage | — | 14.87× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $68.4M | ||
| Q4 25 | $167.9M | $57.3M | ||
| Q3 25 | $92.4M | $85.0M | ||
| Q2 25 | $86.1M | $79.8M | ||
| Q1 25 | $114.6M | $70.4M | ||
| Q4 24 | $144.8M | $191.7M | ||
| Q3 24 | $144.7M | $238.6M | ||
| Q2 24 | $189.3M | $308.4M |
| Q1 26 | — | $391.3M | ||
| Q4 25 | — | $392.8M | ||
| Q3 25 | — | $387.1M | ||
| Q2 25 | — | $394.1M | ||
| Q1 25 | — | $409.2M | ||
| Q4 24 | — | $403.9M | ||
| Q3 24 | — | $399.0M | ||
| Q2 24 | — | $436.8M |
| Q1 26 | — | $26.3M | ||
| Q4 25 | $-302.0M | $-24.6M | ||
| Q3 25 | $-451.4M | $-27.9M | ||
| Q2 25 | $-433.5M | $-29.3M | ||
| Q1 25 | $-426.2M | $-52.4M | ||
| Q4 24 | $-388.7M | $-43.2M | ||
| Q3 24 | $-370.2M | $-77.0M | ||
| Q2 24 | $-344.2M | $-101.9M |
| Q1 26 | — | $806.6M | ||
| Q4 25 | $465.9M | $797.4M | ||
| Q3 25 | $364.0M | $787.7M | ||
| Q2 25 | $347.1M | $770.7M | ||
| Q1 25 | $324.0M | $802.3M | ||
| Q4 24 | $343.8M | $814.0M | ||
| Q3 24 | $314.1M | $867.3M | ||
| Q2 24 | $352.3M | $876.1M |
| Q1 26 | — | 14.87× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $1.2M | ||
| Q3 25 | $-4.3M | $40.8M | ||
| Q2 25 | $-31.4M | $35.6M | ||
| Q1 25 | $-22.6M | $-11.2M | ||
| Q4 24 | $-35.0M | $-26.6M | ||
| Q3 24 | $-35.3M | $12.4M | ||
| Q2 24 | $-7.2M | $-26.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.1M | ||
| Q3 25 | — | $40.7M | ||
| Q2 25 | — | $35.4M | ||
| Q1 25 | — | $-11.2M | ||
| Q4 24 | — | $-26.8M | ||
| Q3 24 | $-35.5M | $12.2M | ||
| Q2 24 | $-7.3M | $-26.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.0% | ||
| Q3 25 | — | 35.4% | ||
| Q2 25 | — | 33.0% | ||
| Q1 25 | — | -13.3% | ||
| Q4 24 | — | -35.6% | ||
| Q3 24 | -68.7% | 15.7% | ||
| Q2 24 | -9.9% | -34.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.3% | 0.3% | ||
| Q2 24 | 0.1% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 13.79× | ||
| Q1 25 | — | -1.33× | ||
| Q4 24 | — | -0.87× | ||
| Q3 24 | — | 0.86× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PRCH
Segment breakdown not available.
